Spots Global Cancer Trial Database for Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis

Official Title: Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis: Correlation Analysis of Prognosis and microRNA Expression

Study ID: NCT02634502

Conditions

Carcinoma, Pancreatic

Interventions

radiofrequency ablation

S-1

Study Description

Brief Summary: This study aims to explore the efficacy and safety of radiofrequency ablation combined with S-1 in pancreatic cancer patients with liver metastasis, as well as the correlation of serum microRNA and patients' prognosis. This protocol will be overseen by the Fudan University Institutional Review Board which has Federal Wide Assurance through the U.S. Department of Health \& Human Services (Approved: April 25, 2002).

Detailed Description: Primary Outcome Measures: To evaluate the overall survival (OS) in pancreatic cancer patients with liver metastasis treated with radiofrequency ablation combined with S-1. Secondary Outcome Measures: 1. To explore the correlation of OS and serum microRNA of the patients. 2. To evaluate the progression free survival (PFS) and its correlation with serum microRNA. 3. To observe the objective response rate (ORR) and adverse effects of the treatment.